KLRSKalaris Therapeutics IncHealthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $3.18 · now $3.18 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, KLRS has typically landed between $1.90 and $4.48 — a range of −40.3% to +40.9% from the issuance price $3.18.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,517 overlapping 1 month windows · 2014-01-152026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($3.18) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where KLRS has typically landed a month from the 2026-09-16 close of $3.18 — the range is history, not a prediction.

$1.9worst · -40.3%$4.48best · +40.9%
  • now $3.18 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $3.04 (-4.4%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.58$3.5
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.9$4.48
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,517 windows spanning 2014-01-15 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-12-26−96.2%−96.3%+0.7%
2024-12-17−96.2%−96.2%+4.3%
2025-01-07−96.1%−96.4%+0.0%
3 best
2014-01-15+4847.0%+0.0%+7441.5%
2025-08-15+103.7%+0.0%+103.7%
2025-11-17+92.3%+0.0%+92.3%

1,517 overlapping windows · 2014-01-152026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~7 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
50%
−19.0%
n=6
Feb
83%
+8.5%
n=6
Mar
17%
−27.2%
n=6
Apr
33%
−10.9%
n=6
May
17%
−11.6%
n=6
Jun
17%
−10.0%
n=6
Jul
50%
+0.1%
n=6
Aug
86%
+23.1%
n=7
Sep
57%
+1.9%
n=7
Oct
17%
−8.1%
n=6
Nov
67%
+6.5%
n=6
Dec
17%
−18.7%
n=6

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$11$22026-05-20: 1 insider purchase, $1.2M — AKKARAJU SRINIVAS2026-03-20: 1 insider sale, $13K — Hagen Brett R2025-12-18: 1 insider purchase, $5.0M — AKKARAJU SRINIVAS2025-12: 1 open-market purchase, $5.0M2026-03: 1 open-market sale, $13K2026-05: 1 open-market purchase, $1.2M↑ buys↓ salesdirector AKKARAJU SRINIVAS — Purchase on 2026-05-20, filed 2 days after the tradeofficer Hagen Brett R — Sale on 2026-03-20, filed 3 days after the tradedirector AKKARAJU SRINIVAS — Purchase on 2025-12-18, filed 61 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-05-20AKKARAJU SRINIVASdirectorPurchase244,300 @ $4.83$1.2M+12.3% of holding−9.6%not yet — horizon still open2,224,147Form 4 · filed 2 days after the trade
2026-03-20Hagen Brett RofficerSale1,915 @ $6.72$13K−100.0% of holding−13.0%not yet — horizon still open0Form 4 · filed 3 days after the trade
2025-12-18AKKARAJU SRINIVASdirectorPurchase479,847 @ $10.42$5.0M+32.0% of holding−7.7%−66.4%1,979,847Form 4 · filed 61 days after the trade
2025-03-26Hagen Brett RofficerSale907 @ $8.97$8K−32.0% of holding−24.1%−64.6%1,925Form 4 · filed 1 day after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

51 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-08-27Vandekop Amy O'LearyofficerAward / grant10,00010,000Form 4
2026-08-01KEATING LAURIEdirectorAward / grant18,00018,000Form 4
2026-07-20Bayko Liisa AnnofficerAward / grant220,000220,000Form 4
2026-06-03Dybbs MichaeldirectorAward / grant9,0009,000Form 4
2026-06-03Hallal DaviddirectorAward / grant9,0009,000Form 4
2026-06-03Jovan-Embiricos MoranadirectorAward / grant9,0009,000Form 4
2026-06-03PATTERSON LEONE DdirectorAward / grant9,0009,000Form 4
2026-06-03Ferrara NapoleonedirectorAward / grant9,0009,000Form 4
2026-06-03ADAMIS ANTHONY PdirectorAward / grant9,0009,000Form 4
2026-06-03AKKARAJU SRINIVASdirectorAward / grant9,0009,000Form 4
2026-05-20AKKARAJU SRINIVASdirectorOther acquisition66,90610,657,028Form 4
2026-05-20AKKARAJU SRINIVASdirectorOther acquisition14,93714,937Form 4
2026-05-20AKKARAJU SRINIVASdirectorOther acquisition4,47119,408Form 4
2026-03-19Feinsod MatthewofficerAward / grant135,000135,000Form 4
2026-03-19Oxtoby AndrewdirectorAward / grant222,000222,000Form 4
2026-03-19Hagen Brett RofficerAward / grant60,80060,800Form 4
2026-03-19Gall MatthewofficerAward / grant95,00095,000Form 4
2025-12-22AKKARAJU SRINIVASdirectorAward / grant1,500,0001,500,000Form 4
2025-11-03Gall MatthewofficerAward / grant235,000235,000Form 4
2025-04-10Dybbs MichaeldirectorAward / grant18,00018,000Form 4
2025-04-10Hallal DaviddirectorAward / grant18,00018,000Form 4
2025-04-10Hagen Brett RofficerAward / grant50,26250,262Form 4
2025-04-10Jovan-Embiricos MoranadirectorAward / grant18,00018,000Form 4
2025-04-10Oxtoby AndrewdirectorAward / grant287,000287,000Form 4
2025-04-10PATEL SAMIR CHANDRAKANTdirectorAward / grant18,00018,000Form 4
2025-04-10PATTERSON LEONE DdirectorAward / grant18,00018,000Form 4
2025-04-10ADAMIS ANTHONY PdirectorAward / grant18,00018,000Form 4
2025-04-10AKKARAJU SRINIVASdirectorAward / grant18,00018,000Form 4
2025-04-10Feinsod MatthewofficerAward / grant70,55170,551Form 4
2025-04-10Feinsod MatthewofficerAward / grant101,000101,000Form 4
2025-04-10Ferrara NapoleonedirectorAward / grant18,00018,000Form 4
2025-03-18Ferrara NapoleonedirectorAward / grant504,000504,000Form 4
2025-03-18Oxtoby AndrewdirectorAward / grant476,611476,611Form 4
2025-03-18PATEL SAMIR CHANDRAKANTdirectorAward / grant252,000252,000Form 4
2025-03-18PATEL SAMIR CHANDRAKANTdirectorAward / grant100,800100,800Form 4
2025-03-18PATEL SAMIR CHANDRAKANTdirectorAward / grant105,913105,913Form 4
2025-03-18ADAMIS ANTHONY PdirectorAward / grant19,48419,484Form 4
2025-03-18ADAMIS ANTHONY PdirectorAward / grant12,98912,989Form 4
2025-03-18AKKARAJU SRINIVASdirectorAward / grant11,444,50311,444,503Form 4
2025-03-18Oxtoby AndrewdirectorAward / grant476,611476,611Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.